Eiger BioPharmaceuticals to Participate in Investor Conferences in August
BTIG Biotechnology Conferenceat St. Regis Hotelin New York City. Eiger will host one-on-one meetings.
Wedbush PacGrow Healthcare Conferenceat Parker New York Hotelin New York City. Eiger will present a corporate update with a live webcast on August 13, 3:05-3:35 PM ET. Eiger will host one-on-one meetings.
The live webcast of the
Eiger is a late-stage biopharmaceutical company focused on the development and commercialization of a pipeline of first-in-class, well-characterized drugs for serious rare and ultra-rare diseases for patients with high unmet medical needs and for which no approved therapies exist.
The Company's lead program is in Phase 3, developing lonafarnib, a first-in-class prenylation inhibitor for the treatment of Hepatitis Delta Virus (HDV) infection. The company is also advancing peginterferon lambda, a first-in-class interferon, toward a Phase 3 study for the treatment of HDV. Eiger is preparing an NDA and MAA for lonafarnib to treat Hutchinson-Gilford Progeria Syndrome (HGPS or Progeria) and Progeroid Laminopathies with plans to file in 2019. For additional information about Eiger and its clinical programs, please visit www.eigerbio.com.
Email: [email protected]
View original content to download multimedia:http://www.prnewswire.com/news-releases/eiger-biopharmaceuticals-to-participate-in-investor-conferences-in-august-300896089.html